ADCendo: entering tumors via MRC2

ADCendo ApS is developing an antibody-drug conjugate against mannose receptor C type 2 (MRC2; UPARAP) that could treat cancers at lower doses and with less toxicity than other ADCs, due to the target’s enriched cancer expression and cellular internalization properties.

MRC2 is an endocytic receptor that internalizes the molecules it binds with high efficiency, delivers them for lysosomal degradation, and then rapidly recycles to the cell surface. MRC2 is highly expressed on sarcomas, glioblastoma and subtypes of acute myelogenous leukemia (AML) and is also found on normal cells lining the bone, but has low expression in other normal cell types. ...